Molecular Typing and Resistance Profile of Acinetobacter baumannii Isolates during the COVID-19 Pandemic: Findings from the “EPIRADIOCLINF” Project
-
Published:2023-10-19
Issue:10
Volume:12
Page:1551
-
ISSN:2079-6382
-
Container-title:Antibiotics
-
language:en
-
Short-container-title:Antibiotics
Author:
Agodi Antonella12ORCID, Montineri Arturo2, Manuele Rosa2, Noto Paola2, Carpinteri Giuseppe2, Castiglione Giacomo2, Grassi Patrizia2, Lazzara Antonio2, Mattaliano Anna Rita2, Granvillano Giuseppa2ORCID, La Mastra Claudia1, La Rosa Maria Clara1, Maugeri Andrea1ORCID, Barchitta Martina1ORCID
Affiliation:
1. Department of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, 95123 Catania, Italy 2. Azienda Ospedaliero-Universitaria Policlinico AOUP “G. Rodolico-San Marco”, 95123 Catania, Italy
Abstract
Due to the COVID-19 pandemic, there has been a shift in focus towards controlling the spread of SARS-CoV-2, which has resulted in the neglect of traditional programs aimed at preventing healthcare-associated infections and combating antimicrobial resistance. The present work aims to characterize the colonization or infection with Acinetobacter baumannii of COVID-19 patients and to identify any clonality between different isolates. Specifically, data and resistance profiles of A. baumannii isolates were prospectively collected from patients recruited by the EPIRADIOCLINF project. Pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST) were used for molecular typing. Overall, we analyzed 64 isolates of A. baumannii from 48 COVID-19 patients. According to our analysis, we have identified the spread of a clonally related isolate, referred to as B. The PFGE pattern B includes four subtypes: B1 (consisting of 37 strains), B2 (11), B3 (5), and B4 (2). Furthermore, in the isolates that were examined using MLST, the most observed sequence type was ST/281. In terms of resistance profiles, 59 out of the total isolates (92.2%) were found to be resistant to gentamicin, carbapenems, ciprofloxacin, and tobramycin. The isolation and identification of A. baumannii from COVID-19 patients, along with the high levels of transmission observed within the hospital setting, highlight the urgent need for the implementation of effective prevention and containment strategies.
Funder
Assessorato della Salute, Regione Siciliana—Progetti Obiettivo di Piano Sanitario Nazionale
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference91 articles.
1. WHO (2015). Global Action Plan on Antimicrobial Resistance. 2. ECDC (2019). Antimicrobial Resistance Tackling the Burden in the European Union, Briefing Note for EU/EEA Countries. 3. Serra-Burriel, M., Keys, M., Campillo-Artero, C., Agodi, A., Barchitta, M., Gikas, A., Palos, C., and López-Casasnovas, G. (2020). Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. PLoS ONE, 15. 4. ECDC (2022). Antimicrobial Resistance Surveillance in Europe 2022–2020 Data. 5. Collignon, P., and Beggs, J.J. (2019). Socioeconomic Enablers for Contagion: Factors Impelling the Antimicrobial Resistance Epidemic. Antibiotics, 8.
|
|